ResearcherHuaian First People’s HospitalNo recent work listed

Ping Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8776-5759; OpenAlex author ID A5100338617. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: 1 paper

Papers 2

The efficacy and safety of gemcitabine-based combination therapy vs. gemcitabine alone for the treatment of advanced pancreatic cancer: a systematic review and… Co-author DOI 10.21037/jgo-22-624 ↗
Stage IA Patients With Pancreatic Ductal Adenocarcinoma Cannot Benefit From Chemotherapy: A Propensity Score Matching Study. Last author DOI 10.3389/fonc.2020.01018 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yibing Zhou · 1 shared paper, 2022 · strength 0.22
- Paper The efficacy and safety of gemcitabine-based combination therapy vs. gemcitabine alone for the treatment of advanced pa… DOI 10.21037/jgo-22-624 ↗
Zhaohuan Zhang · 1 shared paper, 2022 · strength 0.22
- Paper The efficacy and safety of gemcitabine-based combination therapy vs. gemcitabine alone for the treatment of advanced pa… DOI 10.21037/jgo-22-624 ↗
Yuchao Zhang · 1 shared paper, 2020 · strength 0.12
- Paper Stage IA Patients With Pancreatic Ductal Adenocarcinoma Cannot Benefit From Chemotherapy: A Propensity Score Matching S… DOI 10.3389/fonc.2020.01018 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.